Contact Us
Site Map
Log-In
Home
About Us
Our Research
Our People
News
Study Details
Residual risk of cardiovascular disease in patients treated under standard care
Gregory A. Nichols,
Principal Investigator
Pharmaceutical therapies, such as statins, ACE Inhibitors, aspirin and other anti-platelets, have proven effective for patients at risk of cardiovascular disease (CVD). Nevertheless, CVD events still occur, even with intensive treatment. Such residual risk has not been specifically quantified. This study is intended to quantify the risk and cost associated with residual CVD among patients with a previous history of coronary artery disease receiving the current standard of care.
Funding source:
Glaxo SmithKline
Three Regions — One Mission
Each CHR site conducts professionally independent, public domain research and disseminates its findings in the scholarly literature and scientific community.
Northwest
3800 N. Interstate
Portland, OR 97227
503.335.2400
Hawaii
711 Kapiolani Blvd.
Suite 200
Honolulu, HI 96813
101.222.2400
Southeast
3495 Piedmont Road, NE
Ten Piedmont Center,
Suite 205
Atlanta, GA 30305
202.555.1212
